354 related articles for article (PubMed ID: 26657081)
21. Systematic analysis of somatic mutations impacting gene expression in 12 tumour types.
Ding J; McConechy MK; Horlings HM; Ha G; Chun Chan F; Funnell T; Mullaly SC; Reimand J; Bashashati A; Bader GD; Huntsman D; Aparicio S; Condon A; Shah SP
Nat Commun; 2015 Oct; 6():8554. PubMed ID: 26436532
[TBL] [Abstract][Full Text] [Related]
22. Mutational landscape of RNA-binding proteins in human cancers.
Neelamraju Y; Gonzalez-Perez A; Bhat-Nakshatri P; Nakshatri H; Janga SC
RNA Biol; 2018 Jan; 15(1):115-129. PubMed ID: 29023197
[TBL] [Abstract][Full Text] [Related]
23. Systematic analysis of somatic mutations driving cancer: uncovering functional protein regions in disease development.
Mészáros B; Zeke A; Reményi A; Simon I; Dosztányi Z
Biol Direct; 2016 May; 11():23. PubMed ID: 27150584
[TBL] [Abstract][Full Text] [Related]
24. Tissue-Specific Signaling Networks Rewired by Major Somatic Mutations in Human Cancer Revealed by Proteome-Wide Discovery.
Zhao J; Cheng F; Zhao Z
Cancer Res; 2017 Jun; 77(11):2810-2821. PubMed ID: 28364002
[TBL] [Abstract][Full Text] [Related]
25. Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S; Sun SQ; Huang KL; Oh C; Bailey MH; Varghese R; Wyczalkowski MA; Ning J; Tripathi P; McMichael JF; Johnson KJ; Kandoth C; Welch J; Ma C; Wendl MC; Payne SH; Fenyö D; Townsend RR; Dipersio JF; Chen F; Ding L
Genome Med; 2018 Jul; 10(1):60. PubMed ID: 30053901
[TBL] [Abstract][Full Text] [Related]
26. CanDriS: posterior profiling of cancer-driving sites based on two-component evolutionary model.
Zhao W; Yang J; Wu J; Cai G; Zhang Y; Haltom J; Su W; Dong MJ; Chen S; Wu J; Zhou Z; Gu X
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33876217
[TBL] [Abstract][Full Text] [Related]
27. Druggable cancer secretome: neoplasm-associated traits.
Narayanan R
Cancer Genomics Proteomics; 2015; 12(3):119-31. PubMed ID: 25977171
[TBL] [Abstract][Full Text] [Related]
28. iCAGES: integrated CAncer GEnome Score for comprehensively prioritizing driver genes in personal cancer genomes.
Dong C; Guo Y; Yang H; He Z; Liu X; Wang K
Genome Med; 2016 Dec; 8(1):135. PubMed ID: 28007024
[TBL] [Abstract][Full Text] [Related]
29. Pathway and network analysis of more than 2500 whole cancer genomes.
Reyna MA; Haan D; Paczkowska M; Verbeke LPC; Vazquez M; Kahraman A; Pulido-Tamayo S; Barenboim J; Wadi L; Dhingra P; Shrestha R; Getz G; Lawrence MS; Pedersen JS; Rubin MA; Wheeler DA; Brunak S; Izarzugaza JMG; Khurana E; Marchal K; von Mering C; Sahinalp SC; Valencia A; ; Reimand J; Stuart JM; Raphael BJ;
Nat Commun; 2020 Feb; 11(1):729. PubMed ID: 32024854
[TBL] [Abstract][Full Text] [Related]
30. A computational method for clinically relevant cancer stratification and driver mutation module discovery using personal genomics profiles.
Wang L; Li F; Sheng J; Wong ST
BMC Genomics; 2015; 16 Suppl 7(Suppl 7):S6. PubMed ID: 26099165
[TBL] [Abstract][Full Text] [Related]
31. Identifying Driver Interfaces Enriched for Somatic Missense Mutations in Tumors.
Ozturk K; Carter H
Methods Mol Biol; 2019; 1907():51-72. PubMed ID: 30542990
[TBL] [Abstract][Full Text] [Related]
32. Understanding the impacts of missense mutations on structures and functions of human cancer-related genes: A preliminary computational analysis of the COSMIC Cancer Gene Census.
Malhotra S; Alsulami AF; Heiyun Y; Ochoa BM; Jubb H; Forbes S; Blundell TL
PLoS One; 2019; 14(7):e0219935. PubMed ID: 31323058
[TBL] [Abstract][Full Text] [Related]
33. Computational Approaches to Prioritize Cancer Driver Missense Mutations.
Zhao F; Zheng L; Goncearenco A; Panchenko AR; Li M
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30037003
[TBL] [Abstract][Full Text] [Related]
34. Identification of candidate cancer drivers by integrative Epi-DNA and Gene Expression (iEDGE) data analysis.
Li A; Chapuy B; Varelas X; Sebastiani P; Monti S
Sci Rep; 2019 Nov; 9(1):16904. PubMed ID: 31729402
[TBL] [Abstract][Full Text] [Related]
35. Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins.
Rozenblatt-Rosen O; Deo RC; Padi M; Adelmant G; Calderwood MA; Rolland T; Grace M; Dricot A; Askenazi M; Tavares M; Pevzner SJ; Abderazzaq F; Byrdsong D; Carvunis AR; Chen AA; Cheng J; Correll M; Duarte M; Fan C; Feltkamp MC; Ficarro SB; Franchi R; Garg BK; Gulbahce N; Hao T; Holthaus AM; James R; Korkhin A; Litovchick L; Mar JC; Pak TR; Rabello S; Rubio R; Shen Y; Singh S; Spangle JM; Tasan M; Wanamaker S; Webber JT; Roecklein-Canfield J; Johannsen E; Barabási AL; Beroukhim R; Kieff E; Cusick ME; Hill DE; Münger K; Marto JA; Quackenbush J; Roth FP; DeCaprio JA; Vidal M
Nature; 2012 Jul; 487(7408):491-5. PubMed ID: 22810586
[TBL] [Abstract][Full Text] [Related]
36. Structure-Based Analysis Reveals Cancer Missense Mutations Target Protein Interaction Interfaces.
Engin HB; Kreisberg JF; Carter H
PLoS One; 2016; 11(4):e0152929. PubMed ID: 27043210
[TBL] [Abstract][Full Text] [Related]
37. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations.
Carter H; Chen S; Isik L; Tyekucheva S; Velculescu VE; Kinzler KW; Vogelstein B; Karchin R
Cancer Res; 2009 Aug; 69(16):6660-7. PubMed ID: 19654296
[TBL] [Abstract][Full Text] [Related]
38. Understanding genomic alterations in cancer genomes using an integrative network approach.
Wang E
Cancer Lett; 2013 Nov; 340(2):261-9. PubMed ID: 23266571
[TBL] [Abstract][Full Text] [Related]
39. MUFFINN: cancer gene discovery via network analysis of somatic mutation data.
Cho A; Shim JE; Kim E; Supek F; Lehner B; Lee I
Genome Biol; 2016 Jun; 17(1):129. PubMed ID: 27333808
[TBL] [Abstract][Full Text] [Related]
40. Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.
Tang YC; Ho SC; Tan E; Ng AWT; McPherson JR; Goh GYL; Teh BT; Bard F; Rozen SG
Breast Cancer Res; 2018 Mar; 20(1):22. PubMed ID: 29566768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
